Application of sorafenib in preparing medicine for treating encephalomyelitis
By stimulating CD4+ T cells to differentiate into Tregs and then reinfusing them with sorafenib, a gap in the treatment of encephalomyelitis was filled, achieving a significant effect of delaying the course of the disease and providing a new treatment approach.
Patent Information
- Application Number
- CN202211628703.X
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2022-12-16
- Publication Date
- 2024-11-22
- Estimated Expiration
- 2042-12-16
AI Technical Summary
Currently, there is no effective cure for multiple sclerosis (MS) in clinical practice. Existing drugs can only alleviate the symptoms, and patients face economic and psychological burdens. No correlation has been reported between sorafenib and encephalomyelitis and Tregs.
Sorafenib was used to stimulate CD4+ T cells to differentiate into regulatory T cells (Tregs). The number of Tregs was increased through in vitro treatment and then reinfused into EAE mice. The multi-target inhibitory effect of sorafenib was used to delay the course of encephalomyelitis.
Sorafenib significantly increases the number of Tregs, directly treats encephalomyelitis, and significantly delays the course of the disease, providing a new approach for the clinical treatment of encephalomyelitis and demonstrating high safety.
Smart Images

Figure CN116173022B_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the field of biomedical technology, and in particular to the application of sorafenib in preparing a medicine for treating encephalomyelitis. Background Art
[0002] Multiple sclerosis (MS) is an autoimmune disease of the central nervous system, which is mostly chronic and recurrent, and the patient population is mainly young and middle-aged. The characteristic of this disease is that the body's own immune cells mistakenly regard their own tissues as viruses or bacteria, thereby attacking their own tissues and triggering an inflammatory response. In MS, autoimmune cells attack the myelin sheath wrapped around the axons of the central nervous system, and the inflammatory response engulfs and destroys the myelin tissue. Because the body's immune system attacks the axonal myelin protein of its own nervous system, the myelin sheath is destroyed and the conduction of nerve signals is impaired, eventually leading to physical disability. At present, there is no clinical cure for MS. The only way is to use drugs to slow down the progression of MS and control the symptoms. Therefore, the repeated attacks of the disease have placed a heavy economic and psychological burden on patients.
[0003] Regulatory T cells (Treg) are a type of T cell subset that regulates the body's immune function, maintains the immune system's tolerance to its own components, keeps the body in immune homeostasis, and is widely involved in the occurrence and development of autoimmune diseases, allergic diseases, infectious diseases, transplantation, and tumors. The cell phenotype of Treg is CD4 + CD25 + Foxp3 + , which can be divided into naturally occurring natural regulatory T cells (nT-regs) and induced adaptive regulatory T cells (aT-regs or iT-regs), such as Th3 and Tr1. In addition, there are CD8Treg and NKT cells, which are closely related to the occurrence of autoimmune diseases. Their abnormal expression can lead to autoimmune diseases. At present, it is believed that iTreg can be generated by peripheral CD4 + T cells differentiate under the action of transforming growth factor-β1 (TGF-β1).
[0004] Treg is closely related to the occurrence and development of MS. Treg inhibits the activation and proliferation of potential autoreactive T cells in the normal body through active regulation, exerts the characteristics of immunosuppression and immune homeostasis, and plays an important role in patients with autoimmune diseases. Therefore, immunotherapy targeting Treg has broad prospects for the treatment of MS.
[0005] Sorafenib is a multi-target, multi-kinase inhibitor that mainly acts on serine threonine kinases and receptor tyrosine kinases on tumor cells and tumor blood vessels, thereby having the dual effects of inhibiting tumor proliferation and anti-angiogenesis. It can directly inhibit the proliferation of tumor cells by blocking the cell signal transduction pathway mediated by RAF / MEK / ERK, and can also block the formation of tumor angiogenesis by inhibiting VEGFR and platelet-derived growth factor (PDGF) receptors, thereby indirectly inhibiting the growth of tumor cells. In clinical practice, sorafenib is suitable for the treatment of unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and locally recurrent or metastatic, progressive, differentiated thyroid cancer that is difficult to treat with radioactive iodine. However, there are no relevant reports on the correlation between sorafenib and encephalomyelitis and Tregs. Summary of the invention
[0006] Based on the deficiencies in the prior art, the present invention provides the use of sorafenib in preparing a medicament for treating encephalomyelitis.
[0007] The applicant's preliminary research data showed that intraperitoneal injection of sorafenib in mice can significantly slow down the course of encephalomyelitis in mice with autoimmune encephalomyelitis (EAE), and this effect of sorafenib depends on sorafenib to increase the number of Tregs cells. Further, the tail vein of Tregs treated and not treated with sorafenib in vitro was reinfused into EAE mice, and the results of in vivo experiments also showed that compared with EAE mice with Tregs not treated with sorafenib, the EAE mice with Tregs treated with sorafenib had greatly weakened encephalomyelitis. In summary, sorafenib provides a new idea for the treatment of clinical encephalomyelitis.
[0008] The specific technical solutions of the present invention are as follows:
[0009] The present invention provides the use of sorafenib in preparing a medicine for treating encephalomyelitis. The sorafenib is sorafenib itself or a pharmaceutically acceptable salt.
[0010] Sorafenib is used clinically to treat unresectable hepatocellular carcinoma, advanced renal cell carcinoma, and locally recurrent or metastatic, progressive, differentiated thyroid cancer that is difficult to treat with radioactive iodine. Therefore, as a ready-made drug, sorafenib has extremely high safety in the treatment of encephalomyelitis. At the same time, in vivo test results show that intraperitoneal injection of sorafenib can significantly delay the course of EAE mice.
[0011] Preferably, the encephalomyelitis is autoimmune encephalomyelitis.
[0012] In CD4 + Sorafenib was added when T cells differentiated into regulatory T cells, and the concentration of sorafenib used was 1 to 4 μM.
[0013] The results of in vivo experiments showed that compared with EAE mice that were re-infused with Tregs not treated with sorafenib, the encephalomyelitis symptoms of EAE mice that were re-infused with Tregs treated with sorafenib were greatly attenuated.
[0014] The present invention also provides a CD4 + In vitro treatment method for differentiation of T cells into regulatory T cells, in CD4 + When T cells differentiate into regulatory T cells, sorafenib is used to treat CD4 + T cells.
[0015] Preferably, the concentration of sorafenib used is 1-4 μM. The method further comprises inducing the treatment of regulatory T cells, wherein the induction treatment conditions are: using 10 μg / ml anti-IFNγ, 10 μg / ml anti-IL4 and 10 ng / ml TGF-β for plating and inducing differentiation.
[0016] The present invention also provides a medicine, the active ingredient of which comprises regulatory T cells, wherein the regulatory T cells are CD4 + The sorafenib is added to stimulate the differentiation of T cells into regulatory T cells, wherein the sorafenib is sorafenib itself or a pharmaceutically acceptable salt thereof. The concentration of sorafenib used is 1 to 4 μM.
[0017] Preferably, the drug is in the form of a liquid injection. In the present application, regulatory T cells are infused back into EAE mice via the tail vein. The dosage of the liquid injection is 200 μl PBS per mouse, containing 5×10 5 Tregs.
[0018] Beneficial effects of the present invention: The application provided by the present invention, sorafenib can directly treat encephalomyelitis, which is manifested by the ability to significantly delay the course of encephalomyelitis. In vivo and in vitro experiments have proved that the mechanism by which sorafenib can directly treat encephalomyelitis is that sorafenib stimulation can increase the number of Tregs, thereby delaying the course of encephalomyelitis, providing a new idea for the clinical treatment of encephalomyelitis. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] Figure 1 Normal C57 mouse CD4 + The ability of T cells to polarize into Treg cells in vitro with or without sorafenib. Figure 1 The proportion of Treg cells was detected by flow cytometry. Ns means no significant difference, "**" means P < 0.005; "***" means P < 0.001.
[0020] Figure 2Real-time fluorescence quantitative analysis was used to detect the expression level of transcription factor Foxp3 in Treg cells. “***” indicates P < 0.001.
[0021] Figure 3 Myelin oligodendrocyte glycoprotein peptide MOG 35-55 Experimental autoimmune encephalomyelitis (EAE) was induced in mice with or without intraperitoneal injection of sorafenib. Figure 3 The clinical scores of EAE mice treated or not with sorafenib. “*” indicates P<0.05.
[0022] Figure 4 Myelin oligodendrocyte glycoprotein peptide MOG 35-55 Experimental autoimmune encephalomyelitis (EAE) was induced in mice by immunization, and PBS, Tregs treated with sorafenib or not were infused back into the tail vein. Clinical scores of EAE mice in the three groups. "*" indicates P < 0.05. DETAILED DESCRIPTION
[0023] C57 mice were purchased from Jiangsu Jicui Yaokang Biotechnology Co., Ltd.
[0024] Example 1
[0025] T cell sorting.
[0026] (1) The spleen and lymph nodes of C57 mice were taken and squeezed with a syringe piston to prepare a tissue suspension;
[0027] (2) Transfer to a 15 ml conical test tube and allow large pieces to settle to the bottom of the tube or filter through a nylon filter to obtain a single cell suspension;
[0028] (3) Centrifuge the cell suspension at 1500 rpm and 4°C for 5 min and discard the supernatant;
[0029] (4) Resuspend the sample in 2 ml of PBS buffer, take 10 μl of 3% glacial acetic acid for dilution, and count the cells;
[0030] (5) Centrifuge the cells again, discard the supernatant, and resuspend the cells in sorting buffer to adjust the density to 1×10 8 Pieces / ml;
[0031] (6) Using CD4 negative selection kit (EasySepTM Mouse CD4 + CD4 + T cells for subsequent experiments.
[0032] Example 2
[0033] Treg cell differentiation in vitro.
[0034] In a 96-well plate, anti-CD3 (145-2C11, Bio X cell) and anti-CD28 (PV-1, Bio X cell) were diluted with autoclaved PBS to a final concentration of 2 μg / ml, and the plate was coated at 200 μl / well and allowed to stand at 37°C for more than 2 hours. CD4 + T cells, 4 × 10 5 / well for Treg cell differentiation induction.
[0035] The conditions for Treg cell differentiation are as follows: 10 μg / ml anti-IFNγ (BE0054, Bio X cell), 10 μg / ml anti-IL4 (BE0045, Bio X cell) and 10 ng / ml TGF-β (130-095-067, Miltenyi Biotec). Stimulation with or without sorafenib (HY-10201, MedChemExpress) was performed, and the differentiation was performed on day 0 after plating. Treg cells were obtained on day 4 and were used in subsequent experiments.
[0036] Example 3
[0037] Flow cytometry: Wash the cells to be tested once with PBS, centrifuge and resuspend with PBS. Add CD4-PE (12-0041-82, Invitrogen) flow cytometry antibody, incubate on ice or at 4°C in the dark for 30 minutes, neutralize with PBS and centrifuge twice, discard the supernatant, add 1 ml of nuclear disruption solution (00-5523-00, Invitrogen) to each tube, and incubate at room temperature in the dark for 1 hour. Add nuclear disruption buffer (00-5523-00, Invitrogen) for neutralization and centrifugation. After centrifugation, discard the supernatant, resuspend the cells with 100 μl nuclear disruption buffer, add Foxp3 (17-5773-82, Invitrogen) flow cytometry antibody, incubate at 4°C in the dark for 30 minutes, add 1× permeabilization buffer for neutralization, and wash twice. The supernatant was discarded, and the cells were resuspended in an appropriate amount of PBS. Flow cytometric analysis was performed using a NovoCyte flow cytometer (ACEA), and the data were analyzed using FlowJo software. Figure 1 The results showed that sorafenib significantly increased Foxp3 + CD4 + The number of T cells (Treg) increased with the increase of sorafenib stimulation concentration.
[0038] Example 4
[0039] Total RNA from cells treated with sorafenib (4 μM) and untreated cells was extracted according to the instructions of RNAiso Plus from TaKaRa. A total of 1 μg RNA was used as a template to synthesize cDNA by reverse transcription according to the instructions of TaKaRa reverse transcription kit (#RR037A).
[0040] The reverse transcription system was prepared as follows: 5× PrimeScript Buffer (2 μl), Oligo dT Primer (0.5 μl), Random 6mers (0.5 μl), PrimeScript RT Enzyme Mix I (0.5 μl), Total RNA (500 ng), RNaseFree H2O (made up to 10 μl), reverse transcription reaction was carried out at 37°C for 15 minutes, and the enzyme activity was thermally inactivated at 85°C for 5 seconds.
[0041] The synthesized cDNA can be used as a template for the reaction, and the corresponding fluorescent quantitative PCR primers are used to perform quantitative PCR amplification using SYBR PremixEx TaqTM (#RR041A).
[0042] The fluorescence quantitative PCR system was 10 μl: SYBR Mix (5 μl), cDNA template (1 μl), Primer (0.6 μl), and ddH2O (filled to 10 μl).
[0043] The following two-step PCR amplification standard procedure was used: Stag1: pre-denaturation, 95°C for 30 seconds; Stag2: PCR reaction (40 cycles), 95°C for 5 seconds, 60°C for 30 seconds.
[0044] The PCR primer sequences are as follows:
[0045] Actb-F: 5′-atggaggggaatacagccc-3′,
[0046] Actb-R: 5′-ttctttgcagctccttcgtt-3′;
[0047] Foxp3-F: 5′-ctcgtctgaaggcagagt-3′,
[0048] Foxp3-R: 5′-tggcagagaggtattgaggg-3′.
[0049] Figure 2 The results showed that sorafenib significantly increased the gene expression of Foxp3 in Treg.
[0050] Example 5
[0051] Construction of experimental autoimmune encephalomyelitis (EAE) mouse model.
[0052] Prepare reagents: Pertussis toxin PTX (List Biochemicals) was prepared with PBS to a final concentration of 2.5 μg / ml; MOG 35-55 (Qiangyao Biotechnology, MEVGWYRSPFSRVVHLYRNGK) was prepared with PBS to a final concentration of 2 mg / ml; inactivated Mycobacterium tuberculosis (BD, #231141) was dissolved in incomplete Freund's adjuvant (Sigma, F5506) to obtain a complete Freund's adjuvant (CFA) with a concentration of 10 mg / ml. 35-55 Mix with an equal volume of CFA, emulsify into an oil-in-water state, and prepare an immune emulsion for inducing EAE. Each mouse was injected with 200μl of emulsion. The animals were immunized by multi-point subcutaneous injection, that is, subcutaneous injections were made at 4 and 6 o'clock on the head, neck and buttocks of the mice, and 50μl was injected at each point. On the same day, 100μl of PTX was injected into the tail vein, and 100μl of PTX was injected into the tail vein again after an interval of 48 hours. The day of immunization was recorded as day 0. The onset of disease was observed and scored every day. The scoring standard uses a 5-point method: 1 tail weakness; 2 impaired righting reflex and hind limb weakness; 3 hind limb paralysis; 4 forelimb and hind limb paralysis; 5 death.
[0053] The constructed mouse EAE model was intraperitoneally injected with or without sorafenib every 3 days starting from day 0, with each mouse injected with a volume of 100 μl and a dose of 20 mg / kg. The onset of the disease was observed and scored every day. Figure 3 The results showed that intraperitoneal injection of sorafenib could significantly delay the course of EAE mice.
[0054] The mouse EAE model was constructed. At the same time, sorafenib (4 μM) treated and untreated Tregs were obtained according to Example 2. The mice were reinfused into the tail vein on day 0 and day 3. Each mouse was reinfused with 200 μl PBS containing 5×10 5 The onset of disease was observed and scored every day. Figure 4 The results showed that sorafenib-treated Tregs significantly delayed the course of EAE mice.
Claims
1. A CD4 + An in vitro method for treating T cells to differentiate into regulatory T cells, characterized in that In CD4 + When T cells differentiate into regulatory T cells, sorafenib is used to treat CD4 + T cells; The concentration of sorafenib used was 1 to 4 μM; The method also includes induction treatment of regulatory T cells, and the induction treatment conditions are: plating and inducing differentiation using 10 μg / ml anti-IFNγ, 10 μg / ml anti-IL4 and 10 ng / ml TGF-β.
